All In Biotech

NDA 021068 · Esjay Pharma

Rocaltrol

Calcitriol · Oral · Vitamin D3 Analog

Last checked: Nov 20, 2026Latest source record: May 15, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Nov 20, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

162

20 Phase 3, 4 recruiting

FAERS reports

20,257

15,687 serious, 2,692 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2026.

INDICATIONS & USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ROCALTROL · CALCITRIOL 1MCG/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcitriol" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,470
  • diarrhoea1,194
  • off label use1,162
  • chronic kidney disease1,115
  • vomiting1,109
  • dyspnoea1,099
  • renal failure1,058
  • fatigue1,050
  • acute kidney injury973
  • death908
  • drug hypersensitivity882
  • drug ineffective801

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004179
2005245
2006171
2007190
2008282
2009388
2010392
2011400
2012513
2013525
2014541
2015863
20161,153
20171,378
20181,728
20192,327
20201,542
20211,449
20221,158
20231,212
20241,417
20251,212
2026992

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rocaltrol (Calcitriol)

2024 spending

$17K

Beneficiaries

38

74 claims

Per beneficiary

$457

$12.20 per unit

View as table
YearSpending
2020$43,677
2021$41,671
2022$46,389
2023$37,011
2024$17,347

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 740 on PubMed

Sponsor: Esjay Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.